A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients With Metastatic Colorectal Cancer Who Have Failed First-line Therapy
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Sep 2019
Price : $35 *
At a glance
- Drugs Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Biomarker; Pharmacodynamics
- 09 Aug 2018 Planned End Date changed from 1 Feb 2018 to 1 Dec 2018.
- 09 Aug 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Oct 2018.
- 09 Aug 2018 Status changed from recruiting to active, no longer recruiting.